AbbVie, Shire agree on $55B combination

SHARE AbbVie, Shire agree on $55B combination

The drugmaker AbbVie has reached a deal worth roughly $55 billion to combine with British counterpart Shire and become the latest U.S. company to seek an overseas haven from tax rates back home.

The companies said Friday they will create a new company that is incorporated on the British island of Jersey, where Shire currently is incorporated. But the new company will be controlled by shareholders of North Chicago-based AbbVie, who will own about 75 percent of the new company’s stock.

Shire shareholders will receive cash and stock valued at about 53.19 pounds ($91.07) for each of their shares. They will then hold the remaining 25 percent stake in the new company.

U.S.-based companies looking to grow through acquisitions have been searching more fervently in recent years for these overseas combinations known as inversions. But the deals are drawing growing concern from President Barack Obama and members of Congress because they cost the United States billions of dollars in tax revenue.

Walgreen’s Swiss switch idea tied to tax savings, but some see clouds with inversion

Durbin sends Walgreen, AbbVie a tax message (Crain’s)

The future likes Boeing and AbbVie [though it likes Google best]

AbbVie blood cancer drug fast-tracked by FDA

At 35 percent, the United States has the highest corporate income tax rate in the industrialized world, and it also taxes income that is earned in another country and then brought home. That causes some companies to park millions of dollars in overseas accounts.

“Companies like ours need access to our global cash flows,” AbbVie Chairman and CEO Richard A. Gonzalez told analysts on Friday, adding that they need to invest globally and in the United States. “Today, we’re at a disadvantage versus many of our foreign competitors.”

AbbVie executives forecast a tax rate of about 13 percent by 2016 for the new company. AbbVie has said its current rate amounts to roughly 22 percent.

Gonzalez added that AbbVie, which sells the blockbuster anti-inflammatory drug Humira, pursued this deal mainly because it was compelling financially and strategically.

“We wouldn’t be doing it if it was just for the tax impact,” Gonzalez said.

The change in tax rate could save AbbVie as much as $500 million in taxes, estimates Chris Geier, partner-in-charge of Sikich LLP’s investment banking practice.

“Companies are scrambling to get deals done” before lawmakers tighten regulations to slow down tax inversions, Geier said in an interview with the Chicago Sun-Times. “You can’t argue (against tax inversions) from a business perspective, especially when you’re talking about a company with high research and development costs, which AbbVie is.”

AbbVie, which pulled in $18.8 billion in sales last year, started researching Shire last fall. Shire makes the attention deficit hyperactivity disorder medication Vyvanse as well as rare disease and gastrointestinal treatments.

Shire rejected several unsolicited takeover bids before the two companies started talking about a possible deal earlier this month. Shire said Friday its board recommends that shareholders vote for the latest offer, and the deal will create “a well-positioned and focused specialty biopharmaceutical company.”

The companies expect the deal to close in the fourth quarter.

U.S.-traded shares of Shire PLC climbed 72 cents to $254.16 in late-morning trading Friday. Shares of AbbVie Inc. slipped 2 cents to $53.50, while broader U.S. trading indexes climbed less than 1 percent.

Combined, AbbVie and Shire would rank ninth worldwide in prescription drug sales, according to The Wall Street Journal. The company wold have sales of $23.64 billion, putting it just behind AstraZeneca with $24.52 billion and ahead of Eli Lilly at $20.12 billion, the Journal said based on data from EvaluatePharma.

Inversions like AbbVie’s are a prime debate topic in Washington. U.S. Treasury Secretary Jacob Lew told House and Senate leaders earlier this week that Congress should immediately enact legislation retroactive to May that stops the practice while the government works on more comprehensive tax reform.

But Utah Republican Sen. Orrin Hatch said in response that while he agrees on the need for reform, such a move — essentially “constructing a wall around U.S. multinational companies” — carries risks. Those include making the companies more attractive targets for foreign takeovers.

Inversions can take place if shareholders of the foreign entity involved retain more than a 20 percent ownership in the newly merged business. Legally, the foreign company might acquire the U.S. business or the two create a new entity. But the U.S. company often maintains both its corporate headquarters and control of the company.

This overseas move has grown more common among health care companies. Last month, U.S. medical device maker Medtronic Inc. said that it had agreed to buy Ireland-based competitor Covidien for $42.9 billion in cash and stock. The combined company would have executive offices in Ireland, which has a 12.5 percent corporate income tax rate.

Deerfield-based Walgreen Co., the largest drugstore chain in the United States, also is considering a similar move with Swiss health and beauty retailer Alliance Boots. Walgreen bought a 45 percent stake in Alliance Boots a few years ago and has an option to buy the rest of the company. Walgreen has said it will discuss its decision later this month or in August.

TOM MURPHY, AP Business Writer with additional reporting by Sun-Times staff

The Latest
The Chicago Park District should focus instead on upgrading Jackson Park and South Shore courses.
The program mentors young adults dealing with gun violence and helps them get their GEDs. They want to show them “you’re worthy, you’re valid, and this is only one of the many things that you will go on to accomplish,” a CRED employee said.
The four boys were on the front porch of a residence in the 7300 block of South Union Avenue when someone fired shots, police said.
The district and teachers’ union have negotiated all summer in hopes of avoiding the contentious battles of the past two years over pandemic safety.
If the Sky succeed in their bid for a consecutive championship, they will be the first WNBA team to do so in 20 years, and the first Chicago team to achieve that in decades.